Pulmatrix Inc (PULM)

$2.1

+0.01

(+0.48%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $2.08
    $2.10
    $2.10
    downward going graph

    0.95%

    Downside

    Day's Volatility :1.03%

    Upside

    0.08%

    downward going graph
  • $1.55
    $2.75
    $2.10
    downward going graph

    26.19%

    Downside

    52 Weeks Volatility :43.63%

    Upside

    23.63%

    downward going graph

Returns

PeriodPulmatrix IncIndex (Russel 2000)
3 Months
-0.47%
0.0%
6 Months
10.58%
0.0%
1 Year
4.5%
0.0%
3 Years
-85.97%
-21.4%

Highlights

Market Capitalization
7.7M
Book Value
$3.64
Earnings Per Share (EPS)
-2.98
PEG Ratio
0.0
Wall Street Target Price
10.0
Profit Margin
-95.18%
Operating Margin TTM
-380.22%
Return On Assets TTM
-29.99%
Return On Equity TTM
-58.99%
Revenue TTM
11.4M
Revenue Per Share TTM
3.12
Quarterly Revenue Growth YOY
-15.8%
Gross Profit TTM
6.1M
EBITDA
-11.1M
Diluted Eps TTM
-2.98
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Pulmatrix Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 376.19%

Current $2.10
Target $10.00

Company Financials

FY18Y/Y Change
Revenue
153.0K
↓ 54.33%
Net Income
-20.6M
↑ 13.88%
Net Profit Margin
-13.4K%
↓ 8050.02%
FY19Y/Y Change
Revenue
7.9M
↑ 5069.93%
Net Income
-20.4M
↓ 0.84%
Net Profit Margin
-257.79%
↑ 13182.08%
FY20Y/Y Change
Revenue
12.6M
↑ 59.72%
Net Income
-28.5M
↑ 39.84%
Net Profit Margin
-225.7%
↑ 32.09%
FY21Y/Y Change
Revenue
5.2M
↓ 59.09%
Net Income
-22.5M
↓ 21.08%
Net Profit Margin
-435.38%
↓ 209.68%
FY22Y/Y Change
Revenue
6.1M
↑ 17.45%
Net Income
-18.7M
↓ 16.8%
Net Profit Margin
-308.43%
↑ 126.95%
FY23Y/Y Change
Revenue
7.3M
↑ 20.21%
Net Income
-14.1M
↓ 24.59%
Net Profit Margin
-193.49%
↑ 114.94%
Q1 FY23Q/Q Change
Revenue
1.5M
↓ 12.24%
Net Income
-4.3M
↑ 4.97%
Net Profit Margin
-287.59%
↓ 47.13%
Q2 FY23Q/Q Change
Revenue
1.8M
↑ 23.02%
Net Income
-3.8M
↓ 11.48%
Net Profit Margin
-206.94%
↑ 80.65%
Q3 FY23Q/Q Change
Revenue
1.8M
↓ 4.93%
Net Income
-3.8M
↓ 1.1%
Net Profit Margin
-215.29%
↓ 8.35%
Q4 FY23Q/Q Change
Revenue
2.2M
↑ 25.61%
Net Income
-2.1M
↓ 44.81%
Net Profit Margin
-94.6%
↑ 120.69%
Q1 FY24Q/Q Change
Revenue
5.9M
↑ 167.26%
Net Income
825.0K
↓ 139.61%
Net Profit Margin
14.02%
↑ 108.62%
Q2 FY24Q/Q Change
Revenue
1.6M
↓ 73.63%
Net Income
-5.8M
↓ 804.36%
Net Profit Margin
-374.42%
↓ 388.44%
FY18Y/Y Change
Total Assets
14.7M
↓ 7.85%
Total Liabilities
2.9M
↓ 50.71%
FY19Y/Y Change
Total Assets
36.1M
↑ 145.18%
Total Liabilities
25.1M
↑ 771.1%
FY20Y/Y Change
Total Assets
38.2M
↑ 5.74%
Total Liabilities
15.0M
↓ 40.07%
FY21Y/Y Change
Total Assets
58.8M
↑ 54.1%
Total Liabilities
11.4M
↓ 24.36%
FY22Y/Y Change
Total Assets
41.0M
↓ 30.37%
Total Liabilities
9.8M
↓ 13.41%
FY23Y/Y Change
Total Assets
34.0M
↓ 17.08%
Total Liabilities
16.0M
↑ 62.16%
Q1 FY23Q/Q Change
Total Assets
36.1M
↓ 11.95%
Total Liabilities
9.0M
↓ 8.08%
Q2 FY23Q/Q Change
Total Assets
31.4M
↓ 12.94%
Total Liabilities
7.9M
↓ 12.21%
Q3 FY23Q/Q Change
Total Assets
36.8M
↑ 17.13%
Total Liabilities
16.9M
↑ 112.6%
Q4 FY23Q/Q Change
Total Assets
34.0M
↓ 7.65%
Total Liabilities
16.0M
↓ 5.48%
Q1 FY24Q/Q Change
Total Assets
30.4M
↓ 10.5%
Total Liabilities
11.4M
↓ 28.75%
Q2 FY24Q/Q Change
Total Assets
15.8M
↓ 48.08%
Total Liabilities
2.5M
↓ 78.28%
FY18Y/Y Change
Operating Cash Flow
-16.8M
↑ 15.78%
Investing Cash Flow
-19.0K
↓ 74.32%
Financing Cash Flow
15.8M
↑ 13.46%
FY19Y/Y Change
Operating Cash Flow
3.2M
↓ 119.27%
Investing Cash Flow
-58.0K
↑ 205.26%
Financing Cash Flow
17.7M
↑ 12.11%
FY20Y/Y Change
Operating Cash Flow
-12.5M
↓ 486.47%
Investing Cash Flow
-281.0K
↑ 384.48%
Financing Cash Flow
21.0M
↑ 18.5%
FY21Y/Y Change
Operating Cash Flow
-19.7M
↑ 58.03%
Investing Cash Flow
-144.0K
↓ 48.75%
Financing Cash Flow
43.5M
↑ 107.21%
FY22Y/Y Change
Operating Cash Flow
-19.4M
↓ 1.88%
Investing Cash Flow
-86.0K
↓ 40.28%
Financing Cash Flow
1.2M
↓ 97.17%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.9M
↓ 2.34%
Investing Cash Flow
-58.0K
↑ 544.44%
Financing Cash Flow
53.0K
↓ 134.87%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.9M
↓ 0.49%
Investing Cash Flow
-58.0K
↑ 0.0%
Financing Cash Flow
0.0
↓ 100.0%

Technicals Summary

Sell

Neutral

Buy

Pulmatrix Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pulmatrix Inc
Pulmatrix Inc
4.5%
10.58%
4.5%
-85.97%
-86.09%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-11.53%
7.92%
21.76%
83.48%
256.87%
Novo Nordisk A/s
Novo Nordisk A/s
-12.73%
-9.68%
25.05%
134.03%
343.37%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
5.86%
71.74%
59.21%
32.07%
248.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.35%
12.64%
28.18%
152.92%
164.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pulmatrix Inc
Pulmatrix Inc
NA
NA
0.0
0.0
-0.59
-0.3
NA
3.64
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.76
38.76
1.75
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pulmatrix Inc
Pulmatrix Inc
Buy
$7.7M
-86.09%
NA
-95.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
256.87%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$512.4B
343.37%
38.76
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.4B
248.13%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
164.64%
32.84
-4.74%

Insights on Pulmatrix Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 5.88M → 1.55M (in $), with an average decrease of 73.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 825.0K → -5.81M (in $), with an average decrease of 804.4% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 51.5% return, outperforming this stock by 46.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.1% return, outperforming this stock by 118.0%

Institutional Holdings

  • Renaissance Technologies Corp

    3.07%

  • BlackRock Inc

    1.50%

  • Vanguard Group Inc

    0.96%

  • Geode Capital Management, LLC

    0.72%

  • State Street Corp

    0.38%

  • Tower Research Capital LLC

    0.13%

Company Information

pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. the platform, called isperse (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. the isperse powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.

Organization
Pulmatrix Inc
Employees
22
CEO
Mr. Peter Ludlum CMA, MBA
Industry
Health Technology

Discover More

FAQs